Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Recruitment

Liftstream is an executive search recruitment company in the life sciences sector

Dimension Therapeutics Diversifies Leadership with Management and Board Appointment

Dimension Therapeutics, a leading rare disease company advancing novel, liver-directed treatments for diverse genetic disorders has announced that it has expanded its Board of Directors with the elections of Georges Gemayel, Ph.D., former Executive Vice President of Genzyme Corporation, and Arlene M. … Continue reading

Posted in Executive Appointments, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

Hans Schikan appointed Chairman of Complix

Complix, a biopharmaceutical company focused on developing a pipeline of transformative protein therapeutics, called Alphabodies™, mainly focused on oncology and autoimmune diseases, today announced the appointment of Hans Schikan as Chairman of its Board of Directors.   Hans Schikan has more than … Continue reading

Posted in Executive Appointments | Tagged , , , , , , , , , , , , , , , | Leave a comment

Wilson Therapeutics appoints Chief Medical Officer

Fresh from announcing that Hans Schikan, ex-CEO of Prosensa, would be joining the Board of Directors at Wilson Therapeutics, the company have announced the appointment of another Genzyme allumni, Dr. Carl Bjartmar as chief medical officer (CMO). Dr. Bjartmar will … Continue reading

Posted in Executive Appointments | Tagged , , , , , , , , , , , | Leave a comment

Prosensa begins FDA submission process for DMD drug

Authored by James Sheppard The Dutch biotechnology company Prosensa has announced that it has begun the submission process for its Duchenne Muscular Dystrophy (DMD) drug Drisapersen with the FDA. Prosensa has hoped that it will fully file by the year … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , | Leave a comment

Prosensa announces senior management and board appointments

Authored by Karl Simpson Prosensa HoldingsN.V, the drug development company focused on advancing therapies for duchenne muscular dystrophy announced the appointment of Willem W. van Weperen to the new position of chief commercial officer and the addition of Dr. Annalisa Jenkins … Continue reading

Posted in Executive Appointments, Orphan Drugs and Rare Diseases, Recruitment Market | Tagged , , , , , , , , , , , , | Leave a comment

New Enterprise Associates backs veteran rare diseases executive team

Authored by Karl Simpson New Enterprise Associates (NEA) has been showing its increasing appetite for rare disease investments as it puts it recent fund to work. With money already invested in companies like Cydan Corporation (led by Cristina Csimma), KLS … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , | Leave a comment

PTC Therapeutics appoints Chief Medical Officer and communicates CHMP conditional decision

Authored by Karl Simpson For patients living with Duchenne Muscular Dystrophy, last year offered great hope but also disappointment. The momentum was building in the development of exciting new therapies and they were looking forward to the promise of meaningful … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Liftstream Attending World Orphan Drug Congress in Geneva

Authored by Karl Simpson This week sees the World Orphan Drug Congress in Geneva, Switzerland. After a successful WODC event back in April in Washington, we’re looking forward to a very engaging conference with some of the industry’s most illustrious … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

Massachusetts biotech continues to excite with new investments

Authored by Karl Simpson Massachusetts is a booming biotech cluster and this week has seen a number of funding events that once again signal the level of innovation and investor interest the cluster attracts. First up, David Mott’s New Enterprise … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Prosensa, Sarepta, PTC, Summit and DART all contribute to the ubiquity of news in Duchenne

Authored by James Sheppard The Duchenne Muscular Dystrophy market has seen considerable advances  in recent months, with companies Prosensa, PTC Therapeutics, Sarepta Therapeutics, Summit and considerable others announcing regular news on  funding, IPOs, research, clinical and regulatory. Prosensa, the Dutch … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 2 Comments




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap